Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
A Phase II Two-Arm Study of Everolimus and Letrozole +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

This phase II trial studies how well everolimus and letrozole with or without ribociclib work in treating participants with endometrial cancer that has spread to other areas of the body or has come back. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for …

letrozole
hysterectomy
recurrent disease
tumor cells
spiral computed tomography
  • 80 views
  • 26 Jan, 2021
  • 3 locations
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer

This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it …

primary tumor
sodium-iodide symporter
tumor cells
neutrophil count
undifferentiated carcinoma
  • 15 views
  • 27 Jan, 2021
  • 2 locations
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving …

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.

recurrent disease
endocrine therapy
plain x-ray
corticosteroids
renal function
  • 0 views
  • 28 Jan, 2021
  • 1 location
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial Ovarian Primary Peritoneal or Fallopian Tube Cancer

This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back. Niraparib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

hysterectomy
maintenance therapy
endometrial adenocarcinoma recurrent
tumor cells
thromboplastin
  • 21 views
  • 24 Jan, 2021
  • 1 location
Olaparib and Entinostat in Patients With Recurrent Platinum-Refractory Resistant Ovarian Primary Peritoneal Fallopian Tube Cancers

This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Olaparib and entinostat may stop the …

clear cell adenocarcinoma
recurrent disease
luteinizing hormone
tumor cells
cancer of the ovary
  • 0 views
  • 24 Jan, 2021
  • 1 location
Onapristone and Anastrozole in Refractory Estrogen and Progesterone Positive Endometrial Cancer

endometrial cancer with a response rate of 9%. Our hypothesis is that the combination of estrogen and progesterone inhibition will help improve the response rate in patients with estrogen receptor positive

  • 0 views
  • 19 Feb, 2021
  • 2 locations
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

recurrent endometrial carcinoma could prolong PFS and to analyze potential immune biomarker of therapeutic response.

systemic therapy
lenvatinib 4 mg
TACE
anticoagulant
prothrombin
  • 0 views
  • 26 Jan, 2021
  • 1 location
Durvalumab Tremelimumab + Radiotherapy in Gynecologic Cancer

This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: Durvalumab Tremelimumab

hysterectomy
luteinizing hormone
tremelimumab
platinum-based chemotherapy
spiral computed tomography
  • 84 views
  • 13 Feb, 2021
  • 2 locations
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment (recurrent). Talazoparib may stop the growth of tumor cells by blocking some …

metastasis
hysterectomy
luteinizing hormone
tumor cells
endocrine therapy
  • 1 views
  • 25 Jan, 2021
  • 1 location